Elopiprazole

Elopiprazole ( ; developmental code names DU-29840 and DU-29894) is an experimental antipsychotic drug of the phenylpiperazine family which was under development for the treatment of psychotic disorders but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Elopiprazole ( ; developmental code names DU-29840 and DU-29894) is an experimental antipsychotic drug of the phenylpiperazine family which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally.

The drug acts as a dual dopamine D 2 and D 3 receptor antagonist and serotonin 5-HT 1A receptor agonist (K i = 0.45 nM, 1.29 nM, and 1.45 nM, respectively). Conversely, it shows more than 50-fold lower affinity for the serotonin 5-HT 2A and 5-HT 2C receptors and various other targets. Elopiprazole was under development by Solvay Duphar.

It reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1366661325 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.